AMSTERDAM—Christian Klemt, the Chief Financial Officer of uniQure N.V. (NASDAQ:QURE), recently disclosed a stock transaction involving the sale of company shares. According to a filing with the Securities and Exchange Commission, Klemt sold 1,796 ordinary shares on December 9, 2024, at a weighted average price of $7.55 per share, totaling approximately $13,559. The stock, which has seen a notable 35% gain over the past six months, currently trades at $15.30.
The sale of these shares was conducted to cover estimated withholding taxes following the vesting of performance-based restricted share units (PRSUs) that were granted to Klemt in 2021. This transaction was not a discretionary trade but was executed under automatic sale instructions as part of the relevant Performance Share Unit Agreement.
Following this transaction, Klemt holds 166,713 shares of uniQure. The company, headquartered in Amsterdam, is involved in pharmaceutical preparations and continues to be active in the life sciences sector.
In other recent news, uniQure has reported significant developments in its gene therapy programs. The biotechnology firm has secured agreement from the U.S. Food and Drug Administration (FDA) on an accelerated approval submission for its gene therapy product, AMT-130, aimed at treating Huntington's Disease. The company has also initiated a Phase I/II clinical trial for its investigational treatment AMT-162, targeting ALS caused by SOD1 mutations.
Raymond (NS:RYMD) James recently upgraded uniQure's stock from Outperform to Strong Buy, while financial services companies H.C. Wainwright and Stifel maintained a Buy rating. The upgrade followed the company's announcement regarding AMT-130 and was accompanied by a substantial increase in the price target.
In addition to these developments, uniQure has undergone significant organizational restructuring, reducing its workforce by 65% and selling its manufacturing facility in Lexington, Massachusetts, to Genezen. These recent developments reflect the company's progress in the development of gene therapies, with a focus on AMT-130 for Huntington's disease and AMT-162 for ALS. Further discussions with the FDA are anticipated in the first half of 2025 to discuss the statistical analysis plan and technical requirements for the Biologics License Application submission for AMT-130.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.